Cingulate Inc (CING NASDAQ) stock market data APIs
$3.6958
-0.07(-1.9%)
as of November 7, 2025
Try our APIs with
free plan!
Cingulate Inc Financial Data Overview
Price chart is built with
Anychart
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Prev. Close
3.6958
Open
3.6293
High
3.7739
Low
3.6275
52 wk Range
3.28-6.01
Market Cap
20 911 K
P/E Ratio
0.0276
Shares Outstanding
5 606 K
EPS
-1.09
Beta
-0.749
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Cingulate Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cingulate Inc data using free add-ons & libraries
Get Cingulate Inc Fundamental Data
Cingulate Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -17 208 596
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-19
- EPS/Forecast: -0.93
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cingulate Inc News
New
INBX Soars 81% Post-Study; FEMY, CING, CYH Pop After Hours
(RTTNews) - Biotech stocks led the after-hours charge on Thursday, with Inhibrx Biosciences (INBX) skyrocketing over 81% on positive Phase 2 trial results in chondrosarcoma. Femasys (FEMY), Cingulate ...
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizi...
ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Confer...
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
KANSAS CITY, Kan., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
